SCNN1G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18538918	0.98	1/20
SCHEMBL18538914	0.90	1/20
SCHEMBL20348262	0.89	1/20
SCHEMBL18538913	0.85	1/20
SCHEMBL20032722	0.85	1/20
SCHEMBL18538896	0.83	1/20
SCHEMBL18541360	0.81	1/20
SCHEMBL18538902	0.81	1/20
SCHEMBL18538919	0.78	1/20
SCHEMBL20348260	0.78	1/20
SCHEMBL18538917	0.78	1/20
SCHEMBL18538924	0.76	1/20
SCHEMBL18538920	0.75	1/20
SCHEMBL18541357	0.74	1/20
SCHEMBL20032721	0.73	1/20
SCHEMBL18541249	0.73	1/20
SCHEMBL18538897	0.72	1/20
SCHEMBL18538899	0.71	1/20
SCHEMBL21444428	0.71	1/20
SCHEMBL18538911	0.70	1/20

Clinical trials — most relevant to SCNN1G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Double Blind Crossover Comparison of Diuretics in the Young	nan	UNKNOWN
Adverse Airway Effects From Tobacco and E-Cigarettes	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Etiology and Treatment of Neonatal Seizure	nan	RECRUITING
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome	nan	COMPLETED
Hypertension and Urine Protease Activity in Preeclampsia	nan	COMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Painful Channelopathies Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCNN1G binder may also engage these)

Protein	Name	Similarity
Q28738	—	1.000	Q28738 →
Q9WU39	—	1.000	Q9WU39 →
F1MJW3	—	0.999	F1MJW3 →
P37090	—	0.998	P37090 →
H2QAR5	—	0.997	H2QAR5 →
K7FSQ4	—	0.996	K7FSQ4 →
P37091	—	0.996	P37091 →
O97742	—	0.995	O97742 →
O62816	—	0.994	O62816 →
P51171	—	0.993	P51171 →
Q9WU38	—	0.992	Q9WU38 →
P51169	—	0.992	P51169 →
H1AFJ5	—	0.992	H1AFJ5 →
Q95165	—	0.992	Q95165 →
K7FQW8	—	0.991	K7FQW8 →
H1AFJ7	—	0.990	H1AFJ7 →
A5D7U4	—	0.988	A5D7U4 →
SCNN1B	Epithelial sodium channel subunit beta	0.988	landscape →
H1AFJ6	—	0.987	H1AFJ6 →
H2QAR6	—	0.986	H2QAR6 →
O13263	—	0.986	O13263 →
P51167	—	0.984	P51167 →
O13262	—	0.980	O13262 →
Q19038	—	0.976	Q19038 →
Q60NC0	—	0.975	Q60NC0 →
H9GBX2	—	0.974	H9GBX2 →
Q21974	—	0.974	Q21974 →
Q63202	—	0.973	Q63202 →
P24612	—	0.972	P24612 →
Q17298	—	0.972	Q17298 →